Retroscreen has assembled a world class board and senior management team with extensive clinical research and operational experience.

David Norwood, Chairman

David has had a long career building a string of science, technology and investment companies. He is the founder of IP Group plc, one of the UK’s leading technology commercialization businesses. Previously, he was Chief Executive of stockbroker Beeson Gregory (acquired by Evolution Group plc) after it acquired IndexIT Partnership, a technology advisory boutique he had founded in 1999. He was a founding shareholder of Evolution Group plc (recently acquired by Investec), and also co-founder of Ora Capital plc.

David has been a founder and/or director of many UK technology companies including Oxford Nanopore, Proximagen, Synairgen, Ilika, Oxford Catalysts and Plectrum Petroleum (acquired by Cairn Energy). He has also acted as seed investor and/or advisor to Wolfson Microelectronics, Nanoco, Tissue Regenix and Arc International (now part of Synopsys).

A Modern History graduate from Keble College, Oxford, David began his financial career as a foreign exchange trader with Bankers Trust, before specialising in technology companies. David is a former captain of the English chess team and an International Grandmaster at chess. David was appointed Chairman of Retroscreen in February 2011. He is also Non-executive Chairman of Oxford Pharmascience Group plc.

Kym Denny, Chief Executive Officer

Kym Denny was appointed CEO of Retroscreen in December 2010 after serving Retroscreen as Vice President, Clinical Services for a little over a year. She brings with her over fifteen years of international clinical trials senior management experience in Phase I-IV clinical operations, project management, drug safety, data management and site management in therapeutic areas as diverse as infectious disease and respiratory, to CNS, oncology and Women’s Health. Kym began her career as a Clinical Research Associate at Kendle Research. She went on to found InSite Clinical Trials, a hybrid CRO and site management company in Atlanta, Georgia, USA, and then on to the UK where she was appointed to the Board at Profiad, Ltd. in addition to running the Clinical Operations function there. She later became Managing Director, UK, for Harrison Clinical Research before joining Origin as Head of International Clinical Operations, and then as Vice President of Clinical Research when the company was acquired by Constella LLC and later, SRA International. Kym’s unique blend of site management and multi-national clinical trials management helps to drive Retroscreen’s focus on accelerating early phase research in novel antiviral drugs and vaccines.

Professor John Oxford, President, Scientific Director

Professor John Oxford is President, Scientific Director and founder of Retroscreen Virology Ltd and Professor of Virology at St Bartholomew’s and the Royal London Hospital, Queen Mary’s School of Medicine and Dentistry. He has co-authored two standard texts: ‘Influenza, the Viruses and the Disease' with Sir Charles Stuart-Harris and G.C. Schild and most recently, "Human Virology, a Text for Students of Medicine, Dentistry and Microbiology", published by Oxford University Press. Professor Oxford has also published 250 scientific papers.

Charles Winward, Non-Executive Director

Charles is IP Group’s representative on the Board of Retroscreen, having joined in early 2009. Charles joined IP Group in April 2007 to manage investments in Top Technology Ventures, the Group’s venture capital fund management subsidiary. Previously Charles was Vice President Technology Infrastructure at JPMorgan Chase & Co, where he worked in a variety of roles in London, New York and Brussels, and Investment Manager at Axiomlab, an AIM-listed early stage investment specialist. Charles is a CFA charterholder, has an MBA from the University of California at Berkeley and a Bachelors Degree in Mechanical Engineering from the University of Bristol.

Graham Yeatman, Finance Director

Graham joined Retroscreen in May 2011, having previously held senior appointments at Financial Institutions including PriceWaterhouseCoopers where he trained as a Chartered Accountant and was there for 13 years in various assignments both in the UK and abroad. Prior to joining Retroscreen, he was Chief Financial Officer at Neuropharm plc.